Business Model Breakdown
How Transmedics Group Inc Makes Money
TMDX
Market Cap
$3.7B
Annual Revenue
$566M
Profit Margin
31.4%
Employees
728
The Short Version
TransMedics Group Inc. operates by designing, developing, manufacturing, and selling a specialized medical device called the Organ Care System (OCS). The OCS is a portable technology that keeps donor organs, such as hearts, lungs, and livers, viable and functioning outside the human body for an extended period, significantly improving the logistics and outcomes of organ transplantation. The company generates revenue primarily from the sale of these OCS devices and the associated single-use disposable components required for each transplant procedure. Its customers are hospitals and organ procurement organizations globally that perform or facilitate organ transplantation. This business model is centered on pioneering proprietary technology in a critical, high-barrier-to-entry medical field, supported by extensive clinical validation and regulatory approvals.
Where the Revenue Comes From
Sale of Organ Care System (OCS) Consoles and Related Disposables (~95% of revenue)
Service and Maintenance Agreements (~5% of revenue)
Who buys: Hospitals, transplant centers, and Organ Procurement Organizations (OPOs) involved in organ transplantation procedures.
Why It Works (Competitive Advantages)
- ✔Proprietary OCS technology with extensive clinical validation and regulatory approvals (Intangible Assets/IP).
- ✔High switching costs for hospitals due to training, infrastructure, and established clinical protocols.
- ✔Significant regulatory barriers to entry for potential competitors in the organ preservation space.
Economic Moat: Narrow (Intangible Assets/IP, Switching Costs, Regulatory Barriers)
What Our Analysis Says
DVR Score as of April 28, 2026
Transmedics (TMDX) retains its strong position in the organ transplantation market, powered by its proprietary Organ Care System (OCS) and expanding regulatory approvals, including the recent OCS Liver label expansion. The company posted robust FY25 revenue growth of 37% YoY, achieving its first year of GAAP profitability. Its deep competitive moat, built on advanced technology, extensive clinical validation, and regulatory barriers, remains a key asset for long-term market leadership and 10x potential. The recent unveiling of the Controlled Hypothermic Organ Preservation System (CHOPS) for heart/lung trials further strengthens its innovation pipeline and market expansion strategy. While 2026 guidance indicates a deceleration in revenue growth (20-25%), this was already factored into the previous high score. The company's strategic positioning, continued innovation, and profitability trajectory justify its continued high score despite near-term growth modulation.